Improving Adherence and Clinical Outcome in Cystic Fibrosis (CF) Patients
Recruitment status was Not yet recruiting
The purpose of this study is to assess the impact of a collaborative active intervention program of a multi-disciplinary team on improving adherence to chronic medications and improve clinical outcomes in CF patients.
Behavioral: Frequent Scheduled CF clinic visits
Behavioral: frequent telephone calls to patients pre and post visits to the clinic
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Improving Adherence and Clinical Outcomes of Cystic Fibrosis Patients Through a Collaborative Active Intervention Program of a Multidisciplinary Team|
- To determine whether a collaborative intervention program of a multi disciplinary team improves clinical outcomes such as: number of hospital admissions, number of IV ABx courses, and change in %FEV1, BMI. [ Time Frame: 6 months, 12 months ] [ Designated as safety issue: No ]
- To determine whether a collaborative intervention program of a multi disciplinary team improves adherence to routinely prescribed CF medications: Tobi, Pulmozyme, Colistine , HS, Creon and AquADEKs multivitamins. [ Time Frame: 6 months, 12 months ] [ Designated as safety issue: No ]
- To determine whether a collaborative intervention program of a multi-disciplinary team improves health related quality of life. [ Time Frame: 6 months, 12 months ] [ Designated as safety issue: No ]
- To inspect whether improved adherence to medications during intensive care for 1 year in CF will reduce cytokines and inflammatory markers [ Time Frame: 6 months, 12 months ] [ Designated as safety issue: No ]
|Study Start Date:||December 2009|
|Estimated Study Completion Date:||June 2011|
|Estimated Primary Completion Date:||December 2010 (Final data collection date for primary outcome measure)|
Behavioral: Frequent Scheduled CF clinic visits
Cystic fibrosis is a life-threatening hereditary multi-system disease predominantly affecting the pancreas and lungs. Advances in treatment have led to significant improvements in prognosis though this depends crucially upon adherence to treatment.
It has been demonstrated in chronic conditions that improving medication adherence can improve clinical outcome, though it can be a difficult and complex task.
This is the first trial assessing the impact of a collaborative active intervention program of a multi disciplinary team in improving adherence to specific chronic medications and improving clinical outcomes in CF patients.
The trial will be divided into two parts:
First Part The first part of the trial will be a retrospective one in which data will be collected at baseline, from eligible patient files and patients' pharmacy records receiving standard care for the past 12 months.
Second Part The second part of the trial will be an active interventional prospective one and will be conducted for 12 months. The active intervention will be composed of series of visits of patients attending the clinic every 2 months (or sooner, if needed) in which a specialized CF team member will follow on the progress of the patient in his field of expertise. Furthermore, frequent telephone calls for monitoring, educating and identifying barriers in adherence will be made by a designated team member such as the CF nurse or the CF clinical pharmacist.
On identifying problems concerning medication adherence (such as: difficulties receiving medications from the sick fund, unwillingness to do inhaled medications because of allegedly side effects, difficulties in swallowing pills, etc.) solutions will be suggested by the CF team members and will be examined accordingly on the following visits.
Adherence to specific chronic medications will be determined by a short self reported questionnaire, a structured interview with the clinical pharmacist and prescriptions refill history obtained from pharmacy records in every visit to the clinical pharmacist.
Outcomes will be measured from patient's hospital records at baseline, 6 months and 12 months from the starting point. Measured clinical outcomes will be: PFTs, number of hospital admissions, number of exacerbations, number of IV courses, time between each exacerbation, inflammatory markers, BMI, HRQoL.
|Contact: Vardit M Kalamarofirstname.lastname@example.org|
|Pediatric pulmonary unit, The Edmod and Lili Safra children's Hospital, Sheba Medical Center||Recruiting|
|Contact: Vardit M Kalamaro email@example.com|
|Principal Investigator: Ori Efrat, MD|
|Sub-Investigator: Vardit M Kalamaro, BPharm, MSc|
|Principal Investigator:||Ori Efrati, MD||Sheba Medical Center|
|Study Director:||Vardit M Kalamaro, BPharm, MSc||The Israeli Cystic Fibrosis Foundation|
|Study Chair:||Ran Nissan, Pharm D Student||Hebrew University of Jerusalem|